

### REMARKS

By this preliminary amendment, claims 1-30 have been cancelled and claims 31-60 have been added. Support for the claims can be found at least at page 2, lines 16-28; page 13, line 19 through page 15, line 14; and page 16, line 10 through page 21, line 9.


SEQ ID NO: 4 of the specification, found on page 2, line, 22 and in Table 1 on page 14 has been corrected. Support for this correction is found in the article, "Selection of Continuous Epitope Sequences and Their Incorporation..." by Qiu, et al. The article is incorporated by reference on page 1 of the present specification, which means that it is considered part of the original specification. (The article is included with the information disclosure statement filed concurrently with this amendment.) The article clearly shows on page 321, last sentence of column one, and page 323 in Table 1, that the list of synthesized epitope peptides, particularly SEQ ID NO: 4, was intended to be depicted as is shown in the present amendments. Thus, the sequence amendment is purely typographical in nature and is not a substantive change.

Applicants do not believe any fees are associated with this paper, but if necessary, the Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to Perkins Coie's Deposit Account No. 50-2586. If Applicants can do anything more to expedite this application, Applicants ask the Examiner to contact the undersigned at (310) 788-9900.

Respectfully submitted,

PERKINS COIE LLP

Dated: January 26, 2004

By:   
Lauren Sliger  
Reg. No. 51,086

Cust. No. 34055 Perkins Coie LLP  
Patent – LA  
P.O. Box 1208  
Seattle, WA  
98111-1208  
Phone: (310) 788-9900  
Fax: (310) 788-3399